Network Meta-Analysis
Network Meta-Analysis (NMA) · Also known as: Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis
Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
+5 more
When to use it
Use NMA when (1) multiple interventions for the same condition exist, (2) researchers and clinicians need to rank or choose between them, (3) direct head-to-head trials are sparse or absent for some comparisons, (4) a connected network exists (treatments linked directly or indirectly), and (5) you can assess and justify the assumption of consistency. Common applications include drug comparisons (antidepressants, antihypertensives), surgical techniques, rehabilitation interventions, and preventive strategies. NMA is particularly valuable in health technology assessment (HTA) to inform reimbursement decisions across multiple options.
Strengths & limitations
- Enables ranking of all treatments on a single efficacy scale, even when direct trial evidence is absent for some pairs.
- Increases statistical power by borrowing strength from indirect comparisons, improving precision of estimates.
- Provides a comprehensive evidence synthesis for guideline and policy development, reducing reliance on arbitrary or incomplete pairwise meta-analyses.
- Identifies network inconsistencies that may signal heterogeneity, study design bias, or unmeasured effect modifiers.
- Integrates multi-arm trials naturally, avoiding the need to break trials arbitrarily into separate pairwise comparisons.
- Requires strong assumption of consistency (transitivity): that treatment effects are comparable across different trial populations and contexts. Violation invalidates rankings.
- Results depend on the evidence base; sparse networks or unconnected subgraphs reduce precision and may lead to unreliable indirect estimates.
- Computational complexity increases with network size, and Bayesian NMA requires careful specification of prior distributions, which can influence results.
- Assumes all available trials are identified; missing studies (especially negative ones) can bias results via small-study effects.
Frequently asked
What is the difference between direct and indirect comparisons?
A direct comparison comes from trials that randomized patients to both treatment A and treatment B within the same trial. An indirect comparison is inferred from a network: if A is compared to C in Trial 1 and B is compared to C in Trial 2, we can indirectly compare A vs B through their effects relative to C (the common comparator). NMA synthesizes both types.
What is the consistency assumption, and what happens if it is violated?
Consistency (transitivity) assumes that the relative effect of A vs B is the same regardless of which pathway you take through the network. If A is better than C in trials with young patients but C is better than A in trials with elderly patients, the network is inconsistent. Violations suggest that patient populations or study designs differ meaningfully. Check consistency using consistency plots or by fitting a model with inconsistency parameters. If violated, investigate causes and consider stratified or subgroup NMA.
How do I interpret SUCRA, and does a high SUCRA mean a treatment is definitely best?
SUCRA is the cumulative probability of being best, second-best, etc., across the posterior distribution. SUCRA 90% means, across posterior samples, the treatment ranks best about 90% of the time. However, this does not mean it is definitively best in practice. Always inspect credible intervals around point estimates and ranks. If two treatments have overlapping credible intervals or similar SUCRA values, they are not clearly different. SUCRA is useful for ranking but must be paired with absolute effect size interpretation.
When is NMA not appropriate?
Avoid NMA if (1) the network is disconnected (some treatments are not linked, directly or indirectly), (2) evidence suggests strong violations of consistency (e.g., different patient populations or substantially different study designs), (3) heterogeneity is very high and cannot be explained (may indicate a violated consistency assumption), or (4) the network is very sparse (only one or two trials per comparison) and indirect estimates are therefore highly uncertain.
Sources
- Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324. DOI: 10.1002/sim.1201 ↗
- Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997). The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology, 50(6), 683–691. DOI: 10.1016/s0895-4356(97)00049-8 ↗
- Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010). Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine, 29(7–8), 932–944. DOI: 10.1002/sim.3767 ↗
How to cite this page
ScholarGate. (2026, June 4). Network Meta-Analysis (NMA). ScholarGate. https://scholargate.app/en/evidence-synthesis/network-meta-analysis
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Meta-RegressionMeta Analysis↔ compare